The advances and challenges of Gene Therapy for Duchenne Muscular Dystrophy
Open Access
- 1 June 2017
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 1 (1), 019-036
- https://doi.org/10.29328/journal.jgmgt.1001003
Abstract
No abstract availableThis publication has 98 references indexed in Scilit:
- Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy PatientsMolecular Therapy, 2013
- Short Telomeres and Stem Cell Exhaustion Model Duchenne Muscular Dystrophy in mdx/mTR MiceCell, 2010
- Dystrophin Immunity in Duchenne's Muscular DystrophyThe New England Journal of Medicine, 2010
- A Human-Specific Deletion in Mouse Cmah Increases Disease Severity in the mdx Model of Duchenne Muscular DystrophyScience Translational Medicine, 2010
- Generation of redesigned homing endonucleases comprising DNA-binding domains derived from two different scaffoldsNucleic Acids Research, 2009
- Aldehyde Dehydrogenase Activity Identifies a Population of Human Skeletal Muscle Cells With High Myogenic CapacitiesMolecular Therapy, 2009
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human OrgansCell Stem Cell, 2008
- An improved zinc-finger nuclease architecture for highly specific genome editingNature Biotechnology, 2007
- Finishing the euchromatic sequence of the human genomeNature, 2004